These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20959842)

  • 1. Drug interactions should be evaluated in patients.
    Fletcher CV
    Clin Pharmacol Ther; 2010 Nov; 88(5):585-7. PubMed ID: 20959842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
    Reife RA
    Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
    Manchikanti L
    Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do we use drug concentration data to improve the treatment of overdose patients?
    Isbister GK
    Ther Drug Monit; 2010 Jun; 32(3):300-4. PubMed ID: 20431510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of antiretroviral drug interaction studies.
    Kakuda TN; Schöller-Gyüre M
    Curr Opin HIV AIDS; 2008 May; 3(3):313-8. PubMed ID: 19372984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic surrogate end-points in phase I studies?
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):175-9. PubMed ID: 9112140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary and alternative medicine use among individuals participating in research: implications for research and practice.
    Welder GJ; Wessel TR; Arant CB; Schofield RS; Zineh I
    Pharmacotherapy; 2006 Dec; 26(12):1794-801. PubMed ID: 17125440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Principles and perspectives of clinical pharmacology].
    Kaufmann W
    Klin Wochenschr; 1991; 69 Suppl 26():8-12. PubMed ID: 1813734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to assess the drug interaction potential in translational medicine.
    Persiani S; Larger P
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):675-86. PubMed ID: 17014388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From randomized trials to registry studies: translating data into clinical information.
    Brown ML; Gersh BJ; Holmes DR; Bailey KR; Sundt TM
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):613-20. PubMed ID: 18679381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodology of research and practice for the third millennium: evidence-based medicine.
    Perez CA
    Rays; 2000; 25(3):285-308. PubMed ID: 11367894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic development of quinolone antibiotics.
    Schaefer HG; Ahr G; Kuhlmann J
    Int J Clin Pharmacol Ther; 1995 May; 33(5):266-76. PubMed ID: 7655765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to an evidence-based approach to interventional techniques in the management of chronic spinal pain.
    Manchikanti L; Singh V; Helm S; Schultz DM; Datta S; Hirsch JA;
    Pain Physician; 2009; 12(4):E1-33. PubMed ID: 19668280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.